Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...

SAN FRANCISCO, Jan 12 (Reuters) - Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

The Novo Nordisk Foundation announced it was giving an additional $850 million to an institute to help commercialize ...

Pfizer has launched a two-pronged litigation effort to stop Novo Nordisk from acquiring a weight loss drug company, filing a breach of contract suit in the Court of Chancery on Friday and an antitrust ...

Historic grant will fund BioInnovation Institute expansion across Europe through 2035, targeting startups, jobs, and ...

Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ...